Search Results
Your search for ,iII matches 9601 pages
Showing 51 - 100Sitagliptin Added to Standard Prophylaxis Reduces Risk of Acute GVHD Following Alternative Donor Transplantation
Adding the selective, oral dipeptidyl peptidase-4 inhibitor, sitagliptin, to antithymocyte globulin–based prophylaxis significantly reduced the incidence of grade 2 to 4 acute graft-vs-host disease (GVHD) among patients undergoing alternative donor hematopoietic stem-cell transplantation, according ...
Anitocabtagene Autoleucel Shows High Response Rate in Heavily Pretreated Relapsed/Refractory Multiple Myeloma
Anitocabtagene autoleucel (anito-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, produced responses in all treated patients in a phase I study of heavily pretreated relapsed or refractory multiple myeloma, with 79% achieving a...
HER2-Negative Advanced Gastric Cancers: First-Line Retlirafusp Alfa Combination Demonstrates Survival Benefit
The addition of retlirafusp alfa to capecitabine and oxaliplatin (CAPOX) significantly prolonged overall survival compared with chemotherapy alone as first-line treatment for patients with unresectable, locally advanced or metastatic, HER2-negative gastric or gastroesophageal junction...
Matthew Lunning, DO, FACP, on DLBCL: Are frontMIND Data Top of Mind?
The phase III frontMIND trial demonstrated improved outcomes vs R-CHOP in high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), paralleling the POLARIX trial. Despite efficacy, tafasitamab/lenalidomide/R-CHOP has not achieved comparable guideline adoption. Uncertainty...
FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer
On October 8, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients aged 2 years and older with stage III mismatch repair–deficient (dMMR) colon cancer. The FDA...
Robotic Esophagectomy Improves Lymph Node Yield in Esophageal Cancer
According to results from the phase III ROBOT-2 trial published in JAMA Surgery, robot-assisted minimally invasive esophagectomy provided a more radical lymphadenectomy than conventional minimally invasive esophagectomy in patients with esophageal or esophagogastric junction adenocarcinoma. Berlth...
Replacing Intensive Chemotherapy With Blinatumomab Improves Outcomes in High-Risk Pediatric Acute Lymphoblastic Leukemia
Replacing two cycles of intensive chemotherapy with blinatumomab significantly improved event-free survival in children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (ALL), while also reducing several serious treatment-related toxicities. Schrappe et al reported results from...
The Molecular Watchman: Why Measurable Residual Disease Testing Is Redefining Treatment and Surveillance in Colorectal and Bladder Cancers
Implementing a personalized medicine approach in oncology increasingly includes the use of measurable residual disease (MRD) testing to detect molecular evidence of cancer that remains after treatment, enabling more precise risk stratification, earlier intervention, and more informed treatment...
Pediatric and Adolescent Colorectal Carcinoma: A Retrospective Analysis
Rates of advanced-stage colorectal cancer are climbing in young patients, marking a need for increased vigilance, according to data presented during the American Academy of Pediatrics 2026 National Conference & Exhibition (Abstract 02-204). Investigators retrospectively examined the medical...
Tile-Based Radiation Outperforms Postoperative Stereotactic Radiation Therapy in Resected Brain Metastases
According to findings from a phase III trial reported by Weinberg et al in the Journal of Clinical Oncology, intraoperative tile-based radiation therapy with cesium-131 significantly improved surgical bed control compared with postoperative stereotactic radiation therapy in patients undergoing...
Verifying the Seen and Unseen by AI in Cancer Imaging
Artificial intelligence (AI) can be used in medical imaging and diagnostics to enhance physician capabilities, but also to identify features that humans are not able to see. In research settings, AI has already demonstrated that ability to identify biomarkers from routine medical images and guide...
Autonomous AI Triaged Urgent Suspected Skin Cancer Referrals in Real-World Implementation Study
Autonomous artificial intelligence (AI) as a medical device could be used to address rising dermatology service needs, freeing up clinical capacity to provide about 8,500 more dermatology appointments within 16 months, according to findings from a real-world U.K. study presented at the European...
Giannis S. Mountzios, MD, on Metastatic PD-L1–High NSCLC: Sacituzumab Govitecan/Pembrolizumab
Giannis S. Mountzios, MD, of Henry Dunant Hospital Center, reviews primary results from the phase III EVOKE-03/KEYNOTE D46 trial, which evaluated first-line sacituzumab govitecan in combination with pembrolizumab in patients with metastatic non–small cell lung cancer (NSCLC) and a PD-L1 tumor...
ER-Positive, HER2-Negative Advanced Breast Cancer: Giredestrant Plus Everolimus
Patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer experienced significantly improved progression-free survival when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD),...
Pembrolizumab/Olaparib Strategy in BRCA-Nonmutated Advanced Ovarian Cancer
A pembrolizumab/olaparib strategy significantly improved progression-free survival in patients with newly diagnosed BRCA-nonmutated advanced epithelial ovarian cancer, although overall survival was not improved. Ignace Vergote, MD, PhD, and colleagues reported results from the phase III...
IARC Panel Provides International Determination on Lung Cancer Screening's Benefits and Harms
The International Agency for Research on Cancer (IARC) has published a comprehensive international evaluation on lung cancer screening in The New England Journal of Medicine. Screening has emerged as a complementary approach to tobacco control and other methods for preventing lung cancer to reduce...
Multicancer Early Detection Screening Does Not Reduce Overall Late-Stage Cancer Diagnosis
The results of the randomized NHS-Galleri trial reported by Sasieni et al in The New England Journal of Medicine showed that annual screening with a blood-based multicancer early detection test added to usual care did not result in a significantly lower incidence rate of stage III or IV cancers...
Cleveland Clinic London Appoints Oncology Vice Chief
Cleveland Clinic London has appointed Heather Shaw, MD, FRCP, as Oncology Vice Chief, reinforcing the organization’s commitment to expanding access to advanced, multidisciplinary cancer care in the United Kingdom. Dr. Shaw will lead oncology strategy and service development across Cleveland Clinic...
Anne Chiang, MD, PhD, on Targeting B7-H3 in Second-Line SCLC Treatment: Novel ADCs
Anne Chiang, MD, PhD, of Yale University School of Medicine, provides commentary on two China-based phase III studies presented in Presidential Symposium 1: TAISHAN-02, which looked at the antibody-drug conjugate (ADC) tambotatug pelitecan vs topotecan among patients with relapsed small cell lung...
Long-Term Disease Control From SBRT Equal to Surgery in Localized Prostate Cancer
Five-treatment stereotactic body radiation therapy (SBRT) may offer an effective alternative to surgery for patients with localized prostate cancer. In long-term follow-up findings from the phase III PACE-A trial presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting...
New Prognostic Model May Improve Risk Classification in Metastatic Clear Cell RCC
A new prognostic model developed for the checkpoint inhibitor era showed better discrimination of survival outcomes in patients with previously untreated metastatic clear cell renal cell carcinoma (RCC) than the widely used International Metastatic RCC Database Consortium (IMDC) model. The...
SRS Is a "Reasonable Option" for Patients With SCLC and Brain Metastases
Stereotactic radiosurgery demonstrated a prolonged overall survival compared with hippocampal-avoidant whole-brain radiotherapy with memantine in patients with small cell lung cancer (SCLC) and brain metastases, according to phase III study findings presented at the 2026 American Society for...
Fractionated SRS Approach Improves Outcomes for Patients With Resected Large Brain Metastases
Fractionated stereotactic radiosurgery after resection improves surgical bed control compared with single-fraction stereotactic radiosurgery for patients with large brain metastases, according to findings from a phase III trial presented at the 2026 American Society for Radiation Oncology (ASTRO)...
Phase III Trial Compares HER2-Directed Antibody-Drug Conjugates in Advanced Breast Cancer
According to findings from a phase III randomized trial reported by Zhang et al in the Journal of Clinical Oncology, the novel HER2-directed antibody-drug conjugate trastuzumab botidotin significantly prolonged progression-free survival compared with ado-trastuzumab emtansine (T-DM1) in patients...
Old Habits Die Hard: Project Optimus and the Next Generation of KRAS G12C Inhibitors
The recent announcement1 that divarasib, a next-generation KRAS G12C inhibitor, improved both progression-free and overall survival compared with first-generation KRAS G12C inhibitors (ie, sotorasib, adagrasib) is an important scientific milestone in the treatment of KRAS G12C–mutated non–small...
Daraxonrasib Shows Antitumor Activity in Previously Treated RAS-Mutant NSCLC
Daraxonrasib produced responses in more than 30% of patients with previously treated advanced RAS-mutant non–small cell lung cancer (NSCLC), with activity observed across multiple RAS mutations in a phase I/II study. Results from Kathryn C. Arbour, MD, David S. Hong, MD, and colleagues were...
Tambotatug Pelitecan May Improve Survival Outcomes in Relapsed SCLC
The B7-H3–targeting antibody-drug conjugate tambotatug pelitecan significantly improved overall survival compared with topotecan in patients with small cell lung cancer (SCLC) that had progressed after first-line platinum-based therapy, according to results of the phase III TAISHAN-302 trial...
Trastuzumab Rezetecan Improves Progression-Free Survival in Chemotherapy-Refractory HER2-Positive Advanced Colorectal Cancer
The human epidermal growth factor receptor 2 (HER2)–directed antibody-drug conjugate trastuzumab rezetecan significantly improved progression-free survival and produced higher response rates compared with standard-of-care therapy in patients with chemotherapy-refractory, HER2-positive, RAS/RAF...
Excess Mortality Halts Trial of Venetoclax Added to DA-EPOCH-R in Double-Hit Lymphoma
Adding venetoclax to dose-adjusted EPOCH-R (DA-EPOCH-R) did not improve progression-free survival and resulted in excess toxicity and mortality among patients with newly diagnosed double-hit lymphoma, prompting early closure of the double-hit lymphoma cohort of the randomized ALLIANCE A051701...
Neoadjuvant Anbenitamab/Chemotherapy Combination Improves Response in ERBB2-Positive Breast Cancer
Neoadjuvant treatment with the ERBB2-biparatopic antibody anbenitamab plus a solvent-free albumin-bound docetaxel formulation (HB1801) significantly improved total pathologic complete response vs conventional therapy with trastuzumab plus pertuzumab and a taxane (THP) in patients with early or...
Second-Line Investigational Monoclonal Antibody in Metastatic Squamous NSCLC
Patients with metastatic squamous non–small cell lung cancer (NSCLC) whose disease progressed following PD-1/-L1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti–CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving...
Julia Rotow, MD, on Metastatic HER2-Mutant NSCLC: First-Line T-DXd
Julia Rotow, MD, of Dana-Farber Cancer Institute, discusses the primary results from the phase III DESTINY-Lung04 trial, which evaluated first-line trastuzumab deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate, against pembrolizumab plus platinum chemotherapy in patients with...
BRAF Class Alterations in NSCLC Have Different Characteristics, Outcomes, and Co-Mutations, Research Shows
Researchers have identified varying clinicopathologic characteristics and outcomes between patients with non–small cell lung cancer (NSCLC) and class II and III BRAF mutations, according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World...
KEYNOTE-826: Long-Term Outcomes With Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer
Five-year follow-up from the phase III KEYNOTE-826 trial suggests a durable benefit with first-line pembrolizumab plus platinum-based chemotherapy, with or without bevacizumab, in patients with recurrent or metastatic cervical cancer, according to Hasegawa et al in JAMA Oncology. At the first...
TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer
A lower-cost chemoimmunotherapy approach including oral triple metronomic chemotherapy (TMC) combined with ultra-low-dose immunotherapy termed TMC-I could extend survival for patients with advanced head and neck squamous cell carcinoma in resource-limited countries, according to investigators from...
First-Line Amivantamab/Chemotherapy in EGFR Exon 20 Insertion–Positive Advanced NSCLC
Results from the phase III PAPILLON study show that first-line amivantamab plus carboplatin/pemetrexed (amivantamab/chemotherapy) was associated with numerically longer overall survival compared with chemotherapy in patients with previously untreated advanced non–small cell lung cancer (NSCLC)...
Tumor Budding Grading System Can Identify High-Risk Patients With Lung Squamous Cell Carcinoma
A tumor budding–based grading system was able to successfully identify patients with resected lung squamous cell carcinoma who were at a higher risk of poor overall survival and relapse-free survival outcomes, according to findings presented at the International Association for the Study of Lung...
First-Line Trastuzumab Deruxtecan Prolongs PFS in HER2-Mutant NSCLC
Trastuzumab deruxtecan significantly improved progression-free survival over pembrolizumab plus platinum-based chemotherapy for patients with advanced or metastatic HER2-mutant non–small cell lung cancer (NSCLC) who were being treated in the first-line setting, according to phase III DESTINY-Lung04 ...
Zipalertinib Added to Chemotherapy Improves Progression-Free Survival in First-Line EGFR Exon 20 Mutation–Positive NSCLC
The addition of zipalertinib to platinum/pemetrexed chemotherapy led to a significant improvement in progression-free survival in patients with advanced non–small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation, according to phase III findings presented at the International...
OPTIMUM Trial Reports 5-Year Outcomes With Extended Therapy in High-Risk Multiple Myeloma
The 5-year follow-up of the phase II OPTIMUM/MUKnine trial found sustained improvements in progression-free and overall survival with an intensive, risk-adapted treatment strategy for patients with newly diagnosed high-risk multiple myeloma. The findings, reported by Kaiser et al in The Lancet...
Chul Kim, MD, on NSCLC With EGFR Exon 20 Insertions: First-Line Amivantamab/Chemotherapy vs Chemotherapy
Chul Kim, MD, of Georgetown Cancer Institute, reviews findings from the phase III PAPILLON study, which found that first-line amivantamab plus carboplatin/pemetrexed was associated with numerically longer overall survival compared with chemotherapy alone in patients with previously untreated...
PD-L1–High Metastatic NSCLC: First-Line Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Progression-Free Survival Endpoint
Sacituzumab govitecan-hziy plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS)...
Two Phase III Trials Explore B7-H3–Directed ADCs in Relapsed SCLC
Relapsed small cell lung cancer (SCLC) remains a major therapeutic challenge, with limited treatment options and poor outcomes after disease progression on platinum-based chemotherapy and immunotherapy. At the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on...
Long-Term Benefit Seen With Adjuvant Osimertinib in EGFR-Mutated NSCLC
An 8-year update of the phase III ADAURA trial showed that adjuvant osimertinib continued to demonstrate an overall survival benefit over placebo in patients with resected EGFR-mutated non–small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study ...
Izalontamab Brenitecan Active in Previously Treated EGFR-Positive NSCLC
Izalontamab brenitecan (BL-B01D1), an EGFR x HER3 bispecific antibody, demonstrated antitumor activity and a tolerable safety profile, especially at higher dose levels, in patients with previously treated EGFR-mutated metastatic non–small cell lung cancer (NSCLC). These data from a randomized...
Ivonescimab Significantly Improves Overall Survival vs Pembrolizumab in PD-L1–Positive Advanced NSCLC
Ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, was compared with pembrolizumab as first-line treatment for patients with PD-L1–positive advanced non–small cell lung cancer (NSCLC). Data from the prespecified interim analysis of the phase III HARMONi-2 trial were presented at the...
MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for SCLC
Results from the international phase III SWOG S1827 MAVERICK trial show that brain magnetic resonance imaging (MRI) surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC)....
DAROL Examines Darolutamide With Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer
In a post hoc analysis of data from the fourth interim analysis of the DAROL trial, the androgen receptor darolutamide was well tolerated, with no cumulative toxic effects or new safety signals among patients with nonmetastatic castration-resistant prostate cancer receiving concomitant...
Chad G. Rusthoven, MD, on SCLC: Brain MRI Surveillance With or Without Prophylactic Cranial Irradiation
Chad G. Rusthoven, MD, of the University of Colorado School of Medicine, presents results from the international phase III SWOG S1827 MAVERICK trial, which showed that brain MRI surveillance alone improved cognitive failure–free survival compared with MRI surveillance plus prophylactic cranial...
Adjuvant Alectinib Maintains Quality of Life During 2 Years of Treatment in Resected ALK-Positive NSCLC
Adjuvant alectinib was associated with early improvements in health-related quality of life that were maintained over 2 years of treatment in patients with resected ALK-positive non–small cell lung cancer (NSCLC). The new analysis of the phase III ALINA trial, reported by Dziadziuszko et al in The...
